Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The worldwide Parkinsons Disease Drugs market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 8.7% during the forecast period.
This report presents the market size and development trends by detailing the Parkinsons Disease Drugs market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Parkinsons Disease Drugs market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Parkinsons Disease Drugs industry and will help you to build a panoramic view of the industrial development.
Parkinsons Disease Drugs Market, By Type:
Madopar
Sinemet-CR
Trastal
COMT Inhibitor
Other
Parkinsons Disease Drugs Market, By Application:
Hospital
Clinic
Some of the leading players are as follows:
F.Hoffmann-La Roche
Abbvie
Boehringer Ingelheim
Astellas Pharma
Kyowa Hakko Kirin Pharma
Valeant
Novartis
H.Lundbeck
FHoffmann-La Roche
HLundbeck
Teva Pharmaceutical
Desitin Arzneimittel
Endo Pharmaceuticals
Akorn
Stada Arzneimittel
GSK
Orion
Geographically, Major regions are analyzed in details are as follows:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East & Africa
Table of Contents
1 Methodology and Scope
-
1.1 Market Segmentation & Scope
-
1.1.1 Technology Type
-
1.1.2 Product
-
1.1.3 Application
-
1.1.4 Regional scope
-
1.1.5 Estimates and forecast timeline
-
1.2 Research Methodology
-
1.3 Information Procurement
-
1.3.1 Purchased database
-
1.3.2 Internal database
-
1.3.3 Secondary sources
-
1.3.4 Primary research
-
1.3.5 Details of primary research
-
1.4 Information or Data Analysis
-
1.4.1 Data analysis models
-
1.5 Market Formulation & Validation
-
1.6 Model Details
-
1.6.1 Commodity flow analysis
-
1.6.2 Volume price analysis
-
1.7 List of Secondary Sources
-
1.8 List of Abbreviations
2 Executive Summary
-
2.1 Market Outlook
-
2.2 Segment Outlook
3 Market Variables, Trends, & Scope
-
3.1 Market Lineage Outlook
-
3.1.1 Parent market outlook
-
3.1.2 Ancillary market outlook
-
3.2 Market Segmentation
-
3.2.1 Analysis
-
3.3 Market Dynamics
-
3.3.1 Market driver analysis
-
3.3.2 Market restraint analysis
-
3.3.3 Industry opportunities
-
3.4 Penetration & Growth Prospect Mapping
-
3.4.1 Penetration & growth prospect mapping analysis
-
3.5 Business Environment Analysis Tools
-
3.5.1 Porter's five forces analysis
-
3.5.2 PESTLE analysis
-
3.5.3 Major deals & strategic alliances analysis
4 Parkinsons Disease Drugs Market: Technology Type Analysis
-
4.1 Parkinsons Disease Drugs Technology Type Market Share Analysis, 2018 & 2026
-
4.2 Parkinsons Disease Drugs Technology Type Market: Segment Dashboard
-
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment
4.3.1 Madopar
4.3.2 Sinemet-CR
4.3.3 Trastal
4.3.4 COMT Inhibitor
4.3.5 Other
5 Parkinsons Disease Drugs Market: Product Analysis
-
5.1 Parkinsons Disease Drugs Product Market Share Analysis, 2018 & 2026
-
5.2 Parkinsons Disease Drugs Product Market: Segment Dashboard
-
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment
6 Parkinsons Disease Drugs Market: Application Analysis
-
6.1 Parkinsons Disease Drugs Application Market Share Analysis, 2018 & 2026
-
6.2 Parkinsons Disease Drugs Application Market: Segment Dashboard
-
6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment
6.3.1 Hospital
6.3.2 Clinic
7 Parkinsons Disease Drugs Market: Regional Analysis
-
7.1 Parkinsons Disease Drugs Regional Market Share Analysis, 2018 & 2026
-
7.2 Parkinsons Disease Drugs Regional Market: Segment Dashboard
-
7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)
-
7.4 List of Players at Regional Level
-
7.4.1 North America
-
7.4.2 Europe
-
7.4.3 Asia Pacific
-
7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
-
7.5.1 North America
-
7.5.2 Europe
-
7.5.3 Asia Pacific
-
7.5.4 Latin America
-
7.5.5 MEA
-
7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026
-
7.6.1 North America
-
7.6.2 Europe
-
7.6.3 Asia Pacific
-
7.6.4 Latin America
-
7.6.5 Middle East & Africa
8 Competitive Analysis
-
8.1 Recent Developments & Impact Analysis, by Key Market Participants
-
8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)
-
8.3 Vendor Landscape
-
8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)
9 Company Profiles
9.1 F.Hoffmann-La Roche
9.1.1 F.Hoffmann-La Roche Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.1.5 SWOT analysis
9.2 Abbvie
9.2.1 Abbvie Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.2.5 SWOT analysis
9.3 Boehringer Ingelheim
9.3.1 Boehringer Ingelheim Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.3.5 SWOT analysis
9.4 Astellas Pharma
9.4.1 Astellas Pharma Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.4.5 SWOT analysis
9.5 Kyowa Hakko Kirin Pharma
9.5.1 Kyowa Hakko Kirin Pharma Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.5.5 SWOT analysis
9.6 Valeant
9.6.1 Valeant Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.6.5 SWOT analysis
9.7 Novartis
9.7.1 Novartis Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.7.5 SWOT analysis
9.8 H.Lundbeck
9.8.1 H.Lundbeck Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.8.5 SWOT analysis
9.9 FHoffmann-La Roche
9.9.1 FHoffmann-La Roche Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.9.5 SWOT analysis
9.10 HLundbeck
9.10.1 HLundbeck Company overview
9.10.2 Financial performance
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.10.5 SWOT analysis
9.11 Teva Pharmaceutical
9.11.1 Teva Pharmaceutical Company overview
9.11.2 Financial performance
9.11.3 Product benchmarking
9.11.4 Strategic initiatives
9.11.5 SWOT analysis
9.12 Desitin Arzneimittel
9.12.1 Desitin Arzneimittel Company overview
9.12.2 Financial performance
9.12.3 Product benchmarking
9.12.4 Strategic initiatives
9.12.5 SWOT analysis
9.13 Endo Pharmaceuticals
9.13.1 Endo Pharmaceuticals Company overview
9.13.2 Financial performance
9.13.3 Product benchmarking
9.13.4 Strategic initiatives
9.13.5 SWOT analysis
9.14 Akorn
9.14.1 Akorn Company overview
9.14.2 Financial performance
9.14.3 Product benchmarking
9.14.4 Strategic initiatives
9.14.5 SWOT analysis
9.15 Stada Arzneimittel
9.15.1 Stada Arzneimittel Company overview
9.15.2 Financial performance
9.15.3 Product benchmarking
9.15.4 Strategic initiatives
9.15.5 SWOT analysis
9.16 GSK
9.16.1 GSK Company overview
9.16.2 Financial performance
9.16.3 Product benchmarking
9.16.4 Strategic initiatives
9.16.5 SWOT analysis
9.17 Orion
9.17.1 Orion Company overview
9.17.2 Financial performance
9.17.3 Product benchmarking
9.17.4 Strategic initiatives
9.17.5 SWOT analysis
The List of Tables and Figures (Totals 72 Figures and 133 Tables)
Figure Madopar Parkinsons Disease Drugs market, 2015 - 2026 (USD Million)
Figure Sinemet-CR Parkinsons Disease Drugs market, 2015 - 2026 (USD Million)
Figure Trastal Parkinsons Disease Drugs market, 2015 - 2026 (USD Million)
Figure COMT Inhibitor Parkinsons Disease Drugs market, 2015 - 2026 (USD Million)
Figure Other Parkinsons Disease Drugs market, 2015 - 2026 (USD Million)
Figure Hospital market, 2015 - 2026 (USD Million)
Figure Clinic market, 2015 - 2026 (USD Million)
-
Table List of players in North America
-
Table List of players in Europe
-
Table List of players in Asia Pacific
-
Table SWOT analysis
-
Table North America Parkinsons Disease Drugs market, by country, 2015 - 2026 (USD Million)
-
Table North America Parkinsons Disease Drugs market, by type, 2015 - 2026 (USD Million)
-
Table North America Parkinsons Disease Drugs market, by product, 2015 - 2026 (USD Million)
-
Table North America Parkinsons Disease Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.S. Parkinsons Disease Drugs market, by type, 2015 - 2026 (USD Million)
-
Table U.S. Parkinsons Disease Drugs market, by product, 2015 - 2026 (USD Million)
-
Table U.S. Parkinsons Disease Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Canada Parkinsons Disease Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Canada Parkinsons Disease Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Canada Parkinsons Disease Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Europe Parkinsons Disease Drugs market, by country, 2015 - 2026 (USD Million)
-
Table Europe Parkinsons Disease Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Europe Parkinsons Disease Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Europe Parkinsons Disease Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.K. Parkinsons Disease Drugs market, by type, 2015 - 2026 (USD Million)
-
Table U.K. Parkinsons Disease Drugs market, by product, 2015 - 2026 (USD Million)
-
Table U.K. Parkinsons Disease Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Germany Parkinsons Disease Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Germany Parkinsons Disease Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Germany Parkinsons Disease Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table France Parkinsons Disease Drugs market, by type, 2015 - 2026 (USD Million)
-
Table France Parkinsons Disease Drugs market, by product, 2015 - 2026 (USD Million)
-
Table France Parkinsons Disease Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Italy Parkinsons Disease Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Italy Parkinsons Disease Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Italy Parkinsons Disease Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Spain Parkinsons Disease Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Spain Parkinsons Disease Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Spain Parkinsons Disease Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Asia Pacific Parkinsons Disease Drugs market, by country, 2015 - 2026 (USD Million)
-
Table Asia Pacific Parkinsons Disease Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Asia Pacific Parkinsons Disease Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Asia Pacific Parkinsons Disease Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table China Parkinsons Disease Drugs market, by type, 2015 - 2026 (USD Million)
-
Table China Parkinsons Disease Drugs market, by product, 2015 - 2026 (USD Million)
-
Table China Parkinsons Disease Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Japan Parkinsons Disease Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Japan Parkinsons Disease Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Japan Parkinsons Disease Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table India Parkinsons Disease Drugs market, by type, 2015 - 2026 (USD Million)
-
Table India Parkinsons Disease Drugs market, by product, 2015 - 2026 (USD Million)
-
Table India Parkinsons Disease Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Latin America Parkinsons Disease Drugs market, by country, 2015 - 2026 (USD Million)
-
Table Latin America Parkinsons Disease Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Latin America Parkinsons Disease Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Latin America Parkinsons Disease Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Brazil Parkinsons Disease Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Brazil Parkinsons Disease Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Brazil Parkinsons Disease Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Mexico Parkinsons Disease Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Mexico Parkinsons Disease Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Mexico Parkinsons Disease Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Argentina Parkinsons Disease Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Argentina Parkinsons Disease Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Argentina Parkinsons Disease Drugs market, by application, 2015 - 2026 (USD Million)
-
Table MEA Parkinsons Disease Drugs market, by country, 2015 - 2026 (USD Million)
-
Table MEA Parkinsons Disease Drugs market, by type, 2015 - 2026 (USD Million)
-
Table MEA Parkinsons Disease Drugs market, by product, 2015 - 2026 (USD Million)
-
Table MEA Parkinsons Disease Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table South Africa Parkinsons Disease Drugs market, by type, 2015 - 2026 (USD Million)
-
Table South Africa Parkinsons Disease Drugs market, by product, 2015 - 2026 (USD Million)
-
Table South Africa Parkinsons Disease Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Nigeria Parkinsons Disease Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Nigeria Parkinsons Disease Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Nigeria Parkinsons Disease Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Company market position analysis
Table Company Profiles
Table F.Hoffmann-La Roche Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Abbvie Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Boehringer Ingelheim Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Astellas Pharma Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Kyowa Hakko Kirin Pharma Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Valeant Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Novartis Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table H.Lundbeck Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table FHoffmann-La Roche Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table HLundbeck Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Teva Pharmaceutical Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Desitin Arzneimittel Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Endo Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Akorn Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Stada Arzneimittel Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table GSK Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Orion Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
-
